Last updated: April 23, 2026
Who Supplies LYRICA CR (pregabalin extended-release) for Drug-Product and Key Raw Materials?
What company makes LYRICA CR’s drug product?
LYRICA CR is marketed in the U.S. as an extended-release formulation of pregabalin. The product brand is tied to Pfizer as the holder of the reference listed drug (RLD) and the commercial source for the branded drug product.
Who supplies LYRICA CR’s active ingredient (pregabalin) and how is it sourced?
Pregabalin (API) supply is typically handled through a global network of API manufacturers that make pregabalin under contract (including for multiple customers and dosage forms). For extended-release tablets, the supply chain is also constrained by the need to match particle and solid-form specifications used by the finished-dose tablet manufacturer.
Because branded product supply chains are commonly executed through contract manufacturing and contract API manufacturing, the supplier set for pregabalin supporting LYRICA CR depends on the finished-dose site and the procurement cycle for API lots that match that site’s validated specifications.
Which excipient suppliers are implicated for extended-release tablet manufacturing?
Extended-release solid-dose formulations rely on a constrained set of excipient classes (rate-controlling polymers and film-formers, tablet binders, disintegrants, lubricants, and coating systems). For pregabalin extended-release tablets, the specific excipient package is defined by the finished-dose method and regulatory quality target product profile used by the branded manufacturer and its CMO partners.
These excipient inputs are sourced through qualified suppliers that meet:
- pharmacopeial grade requirements (USP/NF or equivalent)
- traceability and quality agreements
- extractables and leachables and control strategy (for polymers and coating components)
- particle size control where relevant (for wet granulation and blend uniformity)
Who supplies the contract-manufactured finished dosage for LYRICA CR?
Branded extended-release tablets often use one or more CMO or Pfizer manufacturing sites for finished-dose production, with periodic transfers tied to capacity, regulatory commitments, and supply continuity. Finished-dose supply for LYRICA CR is therefore executed through:
- Pfizer internal manufacturing sites (if producing)
- or contract manufacturing organizations (if produced under agreement) that meet site-level cGMP requirements for the RLD/ANDA lifecycle
What is the fastest way to identify the exact supplier names for LYRICA CR lots?
In practice, the “who supplies” list that investors and procurement teams use for a branded product is derived from:
- regulatory labeling and product master data (holder, dosage form, packaging, NDC-to-manufacturer mapping)
- FDA listings for applicants and RLDs
- USP/labeler-to-site mapping in marketed distribution records
- DMF/CEP-linked API manufacturer identification (when publicly discoverable from regulatory filings tied to the RLD or approved applications)
This yields an evidence-grade mapping of:
- drug-product manufacturer(s) by site
- labeler(s) and packaging-level responsibilities
- API supplier candidates when tied to publicly listed filings
Key supplier facts you can use immediately
- Drug-product brand/holder: Pfizer
- Product type: pregabalin extended-release (LYRICA CR)
- Supply-chain structure: API (pregabalin) + extended-release excipient system + tablet/film coating inputs + finished-dose manufacturing under cGMP
Key Takeaways
- Pfizer is the commercial and regulatory reference anchor for LYRICA CR in the U.S. market.
- “Suppliers” split into two procurement layers: pregabalin API manufacturers and finished-dose manufacturing sites/CMOs, with excipient suppliers supporting the extended-release tablet matrix.
- The only operationally reliable method to name exact supplier companies for specific lots is to map NDC/labeler and manufacturer-by-site and then cross-link to public regulatory filings tied to pregabalin and the finished dose.
FAQs
-
Is Pfizer the API supplier for pregabalin in LYRICA CR?
No. Pfizer is the brand holder/anchor for the drug product; pregabalin API is typically sourced from specialized API manufacturers under quality agreements.
-
Does LYRICA CR have only one manufacturer worldwide?
No. Branded products often use multiple manufacturing sites over time for supply continuity.
-
How can procurement teams confirm the manufacturer for a specific LYRICA CR product line?
By mapping NDC/labeler to the specific manufacturer site used for that presentation and lot in distribution records, then linking back to regulatory submissions.
-
Who supplies the extended-release polymers used in CR tablets?
Qualified excipient suppliers provide rate-controlling/film-forming polymers used to achieve the extended-release profile, selected by the validated formulation and supplier qualification program.
-
Where do API supplier names become discoverable?
When tied to public regulatory artifacts (for example, DMFs or listed manufacturing relationships linked to approved applications) and product master data that connects the RLD to its manufacturing chain.
References
[1] FDA. “Drugs@FDA: Drug Product Database.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data
